Clinical Trial Update: Study of Gecacitinib in the Treatment of Acute Graft-Versus-Host Disease After Failure of Ruxolitinib-containing Second-line Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Gecacitinib for acute graft-versus-host disease after failure of ruxolitinib-containing second-line therapy; the study is not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Gecacitinib (Gecacitinib)

Snippet

Sponsor: Ruijin Hospital | Conditions: Acute Graft Versus Host Disease Grade II-IV, Acute Graft vs Host Disease | Phase 2 | Status: NOT_YET_RECRUITING